H.C. Wainwright raised the firm’s price target on Neurogene (NGNE) to $65 from $45 and keeps a Buy rating on the shares. The firm says a pediatric neurologist it spoke to sees “clean” safety, same vector/dose, and clearer regulatory footing for NGN-401. H.C. Wainwright upped its probability of sucess to 45% from 35%.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene Inc.’s NGN-401: A Promising Gene Therapy for Rett Syndrome
- Neurogene’s Strategic Advances and Expanded Embolden Trial Drive Buy Rating
- Neurogene’s Favorable Position in CNS Gene Therapy: Buy Rating Backed by Strategic Advantages and Competitive Valuation
- Neurogene Completes FDA Talks for Rett Syndrome Trial
- Neurogene completes FDA discussion on Embolden trial, announces NGN-401 data